Immunotherapy in GU Cancers Articles | Page 3

Combinations Continue to Advance RCC Treatment
Rana R. McKay, MD, discusses the evolving management of patients with advanced RCC, specifically the future of combinations of with immunotherapy regimens.
McDermott Shares Insight on Immunotherapy in RCC
David F. McDermott, MD, discusses the successes with immunotherapy in renal cell carcinoma and gave his insight on the future treatment of these patients.
FDA Grants Pembrolizumab/Lenvatinib Breakthrough Designation for RCC
The FDA has granted the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib a breakthrough therapy designation for the treatment of patients with advanced and/or metastatic renal cell carcinoma.
Japan Approves Pembrolizumab for Urothelial Carcinoma
The Japanese Ministry of Health, Labor and Welfare has approved the use of pembrolizumab for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy
FDA Grants Frontline Avelumab/Axitinib Breakthrough Designation for RCC
The FDA has granted the PD-L1 inhibitor avelumab a breakthrough therapy designation for use in combination with the VEGF inhibitor axitinib in treatment-naïve patients with advanced renal cell carcinoma.
Future of Bladder Cancer Likely to Be Combination Immunotherapy
Arjun Balar, MD, discusses novel immunotherapy combinations for the treatment of patients with bladder cancer.
Pembrolizumab Investigated as Adjuvant RCC Therapy
Tian Zhang, MD, discusses KEYNOTE-564, as well as the progress that immunotherapy has made in the treatment paradigm of patients with RCC.
FDA Grants Nivolumab/Ipilimumab Priority Review for RCC
The FDA has granted a priority review to a sBLA for use of the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced RCC.
Apolo Discusses Managing Immune-Related Toxicities in Bladder Cancer
Andrea Apolo, MD, discusses the management of immune-related adverse events in the treatment of bladder cancer. 
Atezolizumab Plus Bevacizumab Meets Primary Endpoint for PFS in Advanced or Metastatic mRCC
In top-line results from the phase III IMmotion151 trial, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) was associated with a statistically significant reduction in the risk for death or progression in patients with PD-L1
Publication Bottom Border
Border Publication